A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION

Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3–4 weeks) over 1 year. Outcome measures included best-corrected visual… Continue reading →

Posted on September 5th, 2020 in Articles

LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema

SEATTLE, Sept. 3, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute… Continue reading →

LumiThera Closes Series C Round of Financing

SEATTLE, July 8, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage private medical device company, creating a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed its Series C financing. The company raised approximately $14M to support further commercialization of its Valeda Light Delivery System for the treatment for dry… Continue reading →

Photobiomodulation as a Treatment in Dry AMD

Doctors and patients have found this new mode of therapy beneficial. By Hakan Kaymak, MD; and Hartmut Schwahn, PhD The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD… Continue reading →

The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal

Abstract The purpose of this protocol proposal is to suggest a new non-invasive combined therapeutic approach for dry age-related macular degeneration (AMD), an eye disease with no approved treatment or cure. A nutraceutical approach involving dietary supplementation of antioxidants can reduce its risk. Also, photobiomodulation (PBM, or LLLT) has shown promising results with the advantage… Continue reading →

LumiThera to Expand Research into Diabetic Retinopathy for Valeda® Light Delivery System

SEATTLE, Feb. 18, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR). “Recent research in our labs in both preclinical… Continue reading →

LumiThera Adds Daniel Bertholet to Board of Directors

SEATTLE, Jan. 23, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Daniel Bertholet to the Board of Directors. “We are very excited to have Daniel Bertholet join our Board of Directors,” stated Clark Tedford, Ph.D., President and CEO.… Continue reading →

LumiThera Closes 2nd Tranche of Series C Financing

SEATTLE, Jan. 13, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2nd tranche of its Series C round of financing. The proceeds of the financing are being used to support further clinical testing and commercialization of its… Continue reading →

LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

SEATTLE, Oct. 1, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center study called LIGHTSITE III enrolled and treated the… Continue reading →

Valeda Light Delivery System Receives 2019 Medical Design Excellence Award

SEATTLE, June 12, 2019 /PRNewswire/ — LumiThera, Inc. and Product Creation Studio today announced that LumiThera’s Valeda Light Delivery System has been honored with a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2019 in conjunction with the MD&M… Continue reading →